Randomized comparison of metabolic and renal effects of saquinavir/r or atazanavir/r plus tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients

S. M E Vrouenraets, Fwnm Wit, E. Fernandez Garcia, G. J. Moyle, A. G. Jackson, C. Allavena, F. Raffi, Dushyantha T Jayaweera, S. Mauss, C. Katlama, M. Fisher, L. Slama, W. D. Hardy, E. Dejesus, A. van Eeden, P. Reiss

Research output: Contribution to journalArticle

29 Citations (Scopus)

Abstract

Objectives: The aim of the study was to compare the effects on lipids, body composition and renal function of once-daily ritonavir-boosted saquinavir (SQV/r) or atazanavir (ATV/r) in combination with tenofovir/emtricitabine (TDF/FTC) over 48 weeks. Methods: An investigator-initiated, randomized, open-label, multinational trial comparing SQV/r 2000/100mg and ATV/r 300/100mg once daily, both in combination with TDF/FTC, in 123 treatment-naïve HIV-1-infected adults was carried out. The primary endpoint was to demonstrate noninferiority of SQV/r compared with ATV/r with respect to the change in fasting cholesterol after 24 weeks. Secondary outcome measures were changes in metabolic abnormalities, body composition, renal function, and virological and immunological efficacy over 48 weeks. Patients who had used at least one dose of trial drug were included in the analysis. Results: Data for 118 patients were analysed (57 patients on SQV/r and 61 on ATV/r). At week 24, changes in lipids were modest, without increases in triglycerides, including a significant rise in high-density lipoprotein (HDL) cholesterol and a nonsignificant decrease in the total:HDL cholesterol ratio in both arms with no significant difference between arms. Lipid changes at week 48 were similar to the changes observed up to week 24, with no significant change in the homeostasis model assessment (HOMA) index. Adipose tissue increased regardless of the regimen, particularly in the peripheral compartment and to a lesser extent in the central abdominal compartment, with an increase in adipose tissue reaching statistical significance in the ATV/r arm. A slight decline in the estimated glomerular filtration rate (eGFR) was observed in both arms during the first 24 weeks, with no progression thereafter. The immunological and virological responses were similar over the 48 weeks. Conclusions: Combined with TDF/FTC, both SQV/r 2000/100mg and ATV/r 300/100mg had comparable modest effects on lipids, had little effect on glucose metabolism, conserved adipose tissue, and similarly reduced eGFR. The virological efficacy was similar.

Original languageEnglish
Pages (from-to)620-631
Number of pages12
JournalHIV Medicine
Volume12
Issue number10
DOIs
StatePublished - Nov 1 2011

Fingerprint

Tenofovir
Saquinavir
HIV-1
Kidney
Adipose Tissue
Body Composition
Glomerular Filtration Rate
Lipids
HDL Cholesterol
Therapeutics
Ritonavir
Lipoprotein(a)
Atazanavir Sulfate
Emtricitabine
Fasting
Triglycerides
Homeostasis
Cholesterol
Research Personnel
Outcome Assessment (Health Care)

Keywords

  • Adverse effects
  • Atazanavir
  • Saquinavir
  • Tenofovir/emtricitabine

ASJC Scopus subject areas

  • Infectious Diseases
  • Pharmacology (medical)
  • Health Policy

Cite this

Randomized comparison of metabolic and renal effects of saquinavir/r or atazanavir/r plus tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients. / Vrouenraets, S. M E; Wit, Fwnm; Fernandez Garcia, E.; Moyle, G. J.; Jackson, A. G.; Allavena, C.; Raffi, F.; Jayaweera, Dushyantha T; Mauss, S.; Katlama, C.; Fisher, M.; Slama, L.; Hardy, W. D.; Dejesus, E.; van Eeden, A.; Reiss, P.

In: HIV Medicine, Vol. 12, No. 10, 01.11.2011, p. 620-631.

Research output: Contribution to journalArticle

Vrouenraets, SME, Wit, F, Fernandez Garcia, E, Moyle, GJ, Jackson, AG, Allavena, C, Raffi, F, Jayaweera, DT, Mauss, S, Katlama, C, Fisher, M, Slama, L, Hardy, WD, Dejesus, E, van Eeden, A & Reiss, P 2011, 'Randomized comparison of metabolic and renal effects of saquinavir/r or atazanavir/r plus tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients', HIV Medicine, vol. 12, no. 10, pp. 620-631. https://doi.org/10.1111/j.1468-1293.2011.00941.x
Vrouenraets, S. M E ; Wit, Fwnm ; Fernandez Garcia, E. ; Moyle, G. J. ; Jackson, A. G. ; Allavena, C. ; Raffi, F. ; Jayaweera, Dushyantha T ; Mauss, S. ; Katlama, C. ; Fisher, M. ; Slama, L. ; Hardy, W. D. ; Dejesus, E. ; van Eeden, A. ; Reiss, P. / Randomized comparison of metabolic and renal effects of saquinavir/r or atazanavir/r plus tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients. In: HIV Medicine. 2011 ; Vol. 12, No. 10. pp. 620-631.
@article{9360ee207efd4b75a79265b51d623c78,
title = "Randomized comparison of metabolic and renal effects of saquinavir/r or atazanavir/r plus tenofovir/emtricitabine in treatment-na{\"i}ve HIV-1-infected patients",
abstract = "Objectives: The aim of the study was to compare the effects on lipids, body composition and renal function of once-daily ritonavir-boosted saquinavir (SQV/r) or atazanavir (ATV/r) in combination with tenofovir/emtricitabine (TDF/FTC) over 48 weeks. Methods: An investigator-initiated, randomized, open-label, multinational trial comparing SQV/r 2000/100mg and ATV/r 300/100mg once daily, both in combination with TDF/FTC, in 123 treatment-na{\"i}ve HIV-1-infected adults was carried out. The primary endpoint was to demonstrate noninferiority of SQV/r compared with ATV/r with respect to the change in fasting cholesterol after 24 weeks. Secondary outcome measures were changes in metabolic abnormalities, body composition, renal function, and virological and immunological efficacy over 48 weeks. Patients who had used at least one dose of trial drug were included in the analysis. Results: Data for 118 patients were analysed (57 patients on SQV/r and 61 on ATV/r). At week 24, changes in lipids were modest, without increases in triglycerides, including a significant rise in high-density lipoprotein (HDL) cholesterol and a nonsignificant decrease in the total:HDL cholesterol ratio in both arms with no significant difference between arms. Lipid changes at week 48 were similar to the changes observed up to week 24, with no significant change in the homeostasis model assessment (HOMA) index. Adipose tissue increased regardless of the regimen, particularly in the peripheral compartment and to a lesser extent in the central abdominal compartment, with an increase in adipose tissue reaching statistical significance in the ATV/r arm. A slight decline in the estimated glomerular filtration rate (eGFR) was observed in both arms during the first 24 weeks, with no progression thereafter. The immunological and virological responses were similar over the 48 weeks. Conclusions: Combined with TDF/FTC, both SQV/r 2000/100mg and ATV/r 300/100mg had comparable modest effects on lipids, had little effect on glucose metabolism, conserved adipose tissue, and similarly reduced eGFR. The virological efficacy was similar.",
keywords = "Adverse effects, Atazanavir, Saquinavir, Tenofovir/emtricitabine",
author = "Vrouenraets, {S. M E} and Fwnm Wit and {Fernandez Garcia}, E. and Moyle, {G. J.} and Jackson, {A. G.} and C. Allavena and F. Raffi and Jayaweera, {Dushyantha T} and S. Mauss and C. Katlama and M. Fisher and L. Slama and Hardy, {W. D.} and E. Dejesus and {van Eeden}, A. and P. Reiss",
year = "2011",
month = "11",
day = "1",
doi = "10.1111/j.1468-1293.2011.00941.x",
language = "English",
volume = "12",
pages = "620--631",
journal = "HIV Medicine",
issn = "1464-2662",
publisher = "Wiley-Blackwell",
number = "10",

}

TY - JOUR

T1 - Randomized comparison of metabolic and renal effects of saquinavir/r or atazanavir/r plus tenofovir/emtricitabine in treatment-naïve HIV-1-infected patients

AU - Vrouenraets, S. M E

AU - Wit, Fwnm

AU - Fernandez Garcia, E.

AU - Moyle, G. J.

AU - Jackson, A. G.

AU - Allavena, C.

AU - Raffi, F.

AU - Jayaweera, Dushyantha T

AU - Mauss, S.

AU - Katlama, C.

AU - Fisher, M.

AU - Slama, L.

AU - Hardy, W. D.

AU - Dejesus, E.

AU - van Eeden, A.

AU - Reiss, P.

PY - 2011/11/1

Y1 - 2011/11/1

N2 - Objectives: The aim of the study was to compare the effects on lipids, body composition and renal function of once-daily ritonavir-boosted saquinavir (SQV/r) or atazanavir (ATV/r) in combination with tenofovir/emtricitabine (TDF/FTC) over 48 weeks. Methods: An investigator-initiated, randomized, open-label, multinational trial comparing SQV/r 2000/100mg and ATV/r 300/100mg once daily, both in combination with TDF/FTC, in 123 treatment-naïve HIV-1-infected adults was carried out. The primary endpoint was to demonstrate noninferiority of SQV/r compared with ATV/r with respect to the change in fasting cholesterol after 24 weeks. Secondary outcome measures were changes in metabolic abnormalities, body composition, renal function, and virological and immunological efficacy over 48 weeks. Patients who had used at least one dose of trial drug were included in the analysis. Results: Data for 118 patients were analysed (57 patients on SQV/r and 61 on ATV/r). At week 24, changes in lipids were modest, without increases in triglycerides, including a significant rise in high-density lipoprotein (HDL) cholesterol and a nonsignificant decrease in the total:HDL cholesterol ratio in both arms with no significant difference between arms. Lipid changes at week 48 were similar to the changes observed up to week 24, with no significant change in the homeostasis model assessment (HOMA) index. Adipose tissue increased regardless of the regimen, particularly in the peripheral compartment and to a lesser extent in the central abdominal compartment, with an increase in adipose tissue reaching statistical significance in the ATV/r arm. A slight decline in the estimated glomerular filtration rate (eGFR) was observed in both arms during the first 24 weeks, with no progression thereafter. The immunological and virological responses were similar over the 48 weeks. Conclusions: Combined with TDF/FTC, both SQV/r 2000/100mg and ATV/r 300/100mg had comparable modest effects on lipids, had little effect on glucose metabolism, conserved adipose tissue, and similarly reduced eGFR. The virological efficacy was similar.

AB - Objectives: The aim of the study was to compare the effects on lipids, body composition and renal function of once-daily ritonavir-boosted saquinavir (SQV/r) or atazanavir (ATV/r) in combination with tenofovir/emtricitabine (TDF/FTC) over 48 weeks. Methods: An investigator-initiated, randomized, open-label, multinational trial comparing SQV/r 2000/100mg and ATV/r 300/100mg once daily, both in combination with TDF/FTC, in 123 treatment-naïve HIV-1-infected adults was carried out. The primary endpoint was to demonstrate noninferiority of SQV/r compared with ATV/r with respect to the change in fasting cholesterol after 24 weeks. Secondary outcome measures were changes in metabolic abnormalities, body composition, renal function, and virological and immunological efficacy over 48 weeks. Patients who had used at least one dose of trial drug were included in the analysis. Results: Data for 118 patients were analysed (57 patients on SQV/r and 61 on ATV/r). At week 24, changes in lipids were modest, without increases in triglycerides, including a significant rise in high-density lipoprotein (HDL) cholesterol and a nonsignificant decrease in the total:HDL cholesterol ratio in both arms with no significant difference between arms. Lipid changes at week 48 were similar to the changes observed up to week 24, with no significant change in the homeostasis model assessment (HOMA) index. Adipose tissue increased regardless of the regimen, particularly in the peripheral compartment and to a lesser extent in the central abdominal compartment, with an increase in adipose tissue reaching statistical significance in the ATV/r arm. A slight decline in the estimated glomerular filtration rate (eGFR) was observed in both arms during the first 24 weeks, with no progression thereafter. The immunological and virological responses were similar over the 48 weeks. Conclusions: Combined with TDF/FTC, both SQV/r 2000/100mg and ATV/r 300/100mg had comparable modest effects on lipids, had little effect on glucose metabolism, conserved adipose tissue, and similarly reduced eGFR. The virological efficacy was similar.

KW - Adverse effects

KW - Atazanavir

KW - Saquinavir

KW - Tenofovir/emtricitabine

UR - http://www.scopus.com/inward/record.url?scp=80054840461&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80054840461&partnerID=8YFLogxK

U2 - 10.1111/j.1468-1293.2011.00941.x

DO - 10.1111/j.1468-1293.2011.00941.x

M3 - Article

C2 - 21819530

AN - SCOPUS:80054840461

VL - 12

SP - 620

EP - 631

JO - HIV Medicine

JF - HIV Medicine

SN - 1464-2662

IS - 10

ER -